Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells

25 Nov 2011

Abstract excerpt

Imatinib, a breakpoint cluster region (BCR)-Abelson murine leukemia(ABL) tyrosine kinase inhibitor (TKI), has revolutionized the treatment of chronic myelogenous leukemia (CML). However, development of multidrug resistance(MDR) limits the use of imatinib. In the present study, we aimed to investigate the mechanisms of cellular resistance to imatinib in CML. Therefore, we established an imatinib-resistant human...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Myeloid Leukemia Treatments
Share to Diabetes Treatment and Management
Share to Drug Transport and Resistance Mechanisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22098951
DOI: 10.5732/cjc.011.10327

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cellsPMID 22098951Read ↗

Contribution of BCR–ABL‐independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cellsSemantic proximity Read ↗

Development of imatinib and dasatinib resistance: dynamics of expression of drug transportersABCB1, ABCC1, ABCG2, MVP, and SLC22A1Semantic proximity Read ↗

Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patientsSemantic proximity Read ↗

Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cellsSemantic proximity Read ↗

miR-495-3p Sensitizes BCR::ABL1 Expressing Leukemic cells to Tyrosine Kinase Inhibitors by Targeting Multidrug Resistance 1 Gene including in T315I Mutated cellsSemantic proximity Read ↗

Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.Semantic proximity Read ↗

Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia.Semantic proximity Read ↗

Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinibSemantic proximity Read ↗

[Multiple drug resistance].Semantic proximity Read ↗

MicroRNA profiling in K-562 cells under imatinib treatmentSemantic proximity Read ↗

BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia.Semantic proximity Read ↗

Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR–CML cell lines?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.